Poplar Therapeutics

📍 Boston, United States👥 11 employees💰 Last funded Oct 2024
Biotechnology Research🌐 poplartx.com
Website LinkedIn
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Poplar Therapeutics?
Poplar Therapeutics has 1 investors on record on gritt.io.
When did Poplar Therapeutics last raise funding?
The most recent investment in Poplar Therapeutics recorded on gritt.io was in October 2024.
What industry is Poplar Therapeutics in?
Poplar Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Poplar Therapeutics based?
Poplar Therapeutics is headquartered in Boston, United States.